BioNTech Plunges Deeper Into the Red as Shareholders Vote on Board Renewal and €129M Capital Mandate

BioNTech targets oncology transformation at its AGM, seeking capital flexibility and board expertise while managing Q1 losses with a €16.8B cash reserve.

The numbers from BioNTech’s first quarter paint a stark picture. Revenue tumbled to €118.1 million from €182.8 million a year earlier, while the net loss ballooned to €531.9 million. Research spending alone swallowed €557 million. Yet the company sits on a cash hoard of €16.8 billion, giving it the financial cushion to weather the storm as it executes a radical transformation from a pandemic vaccine powerhouse to a pure-play oncology group.

Against that backdrop, shareholders are being asked today to approve a slate of governance and financial changes during a virtual annual general meeting that began at 14:00 MESZ. The agenda is heavy with structural reforms designed to lock in the new strategic direction and give management the firepower to fund it over the long haul.

The supervisory board is set to expand from six to eight seats. Three existing members are standing for re-election, while two new specialists in oncology and clinical development are proposed for co-option — a clear signal that BioNTech wants deep industry expertise at the top table as it accelerates its cancer push. In parallel, a fresh authorized capital resolution seeks permission to issue new shares totaling up to €129.5 million, representing 50% of current share capital. This 2026 mandate would replace the existing 2025 authorization and remain in effect until 2030, giving the board flexible access to equity markets if needed.

A profit and loss transfer agreement with the newly formed subsidiary BioNTech Discovery GmbH is also up for a vote. The structure funnels all future profits and losses from the subsidiary directly to the parent, centralizing the founders' control over the company's next-generation mRNA research.

To conserve cash, BioNTech is shuttering multiple production facilities in Germany and Singapore. The annual cost savings from these closures are expected to reach €500 million, and that money is being redirected straight into the oncology pipeline. The company has also outlined a share buyback program for American Depositary Shares worth up to $1 billion over twelve months, intended to cover equity-based compensation obligations.

The market’s patience is being tested. Berenberg recently trimmed its price target on the stock to $140 from $155, though it maintained a buy rating and described the equity as “deeply” undervalued. The investment case hinges on clinical catalysts: BioNTech plans to file for regulatory approval of the antibody Pumitamig later this year and expects to deliver six data packages from late-stage studies across immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. Six new phase 3 trials are slated for 2026, which would bring the total number of active phase 3 programs to 15.

The stock is trading around €77 to €78, roughly 5% lower year-to-date and some 24% below its 52-week high of nearly €102. It sits about 6% above the 52-week trough of €72.50 and remains below all relevant moving averages. Management has branded 2026 a pivotal year: if the upcoming data readouts in lung and gynecological cancers deliver, the costly restructuring could finally begin to pay off.